{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
GoodRx Holdings, Inc.
GoodRx Holdings Hits 52-Week Low at $3.21 Amidst Significant Decline
GoodRx Holdings, Inc. has hit a new 52-week low, reflecting a significant decline over the past year. Despite this downturn, the company reported positive financial metrics, including strong operating cash flow and net profit. Institutional investors maintain a substantial stake, indicating confidence in its fundamentals.
GoodRx Holdings Hits 52-Week Low at $3.25 Amid Significant Decline
GoodRx Holdings, Inc. has reached a new 52-week low, reflecting a significant decline over the past year. Despite this downturn, the company reported strong financial metrics, including high operating cash flow and net profit. GoodRx also has a substantial market capitalization and high institutional ownership, indicating investor confidence.
Is GoodRx Holdings, Inc. overvalued or undervalued?
As of October 17, 2025, GoodRx Holdings, Inc. is considered fairly valued but overvalued based on key metrics, with a P/E ratio of 38 and a significant underperformance of -44.33% over the past year compared to the S&P 500's 14.08%.
Is GoodRx Holdings, Inc. overvalued or undervalued?
As of October 17, 2025, GoodRx Holdings, Inc. is fairly valued with a P/E ratio of 38, an EV to EBITDA ratio of 9.64, and a Price to Book Value of 2.23, indicating a reasonable valuation compared to peers despite its higher P/E ratio.
Is GoodRx Holdings, Inc. overvalued or undervalued?
As of October 17, 2025, GoodRx Holdings, Inc. is considered overvalued with a fair valuation grade, reflected by high key ratios and significant declines in stock performance, including a 1-year return of -44.33% and a 5-year return of -92.78%.
GoodRx Holdings, Inc. Experiences Valuation Adjustment Amidst Competitive Market Landscape
GoodRx Holdings, Inc. has recently adjusted its valuation, with a P/E ratio of 38 and a Price to Book Value of 2.23. The company shows mixed performance metrics, including a year-to-date return of -1.51% and a decline of 35.40% over the past year, compared to the S&P 500.
Is GoodRx Holdings, Inc. overvalued or undervalued?
As of October 3, 2025, GoodRx Holdings, Inc. is considered overvalued with a valuation grade of expensive, reflected by a high P/E ratio of 38 and underperformance over the past year, despite a recent 1-week return of 12.13%.
GoodRx Holdings, Inc. Experiences Revision in Its Stock Evaluation Amid Competitive Pressures
GoodRx Holdings, Inc. has recently adjusted its valuation, with a P/E ratio of 38 and a price-to-book value of 2.23. The company reports a return on capital employed of 11.40% and a return on equity of 5.92%, reflecting its operational efficiency amid competitive pressures.
Is GoodRx Holdings, Inc. technically bullish or bearish?
As of September 8, 2025, GoodRx Holdings, Inc. is in a bearish trend with weak strength indicators, as shown by the MACD and KST, and has significantly underperformed the S&P 500 with a 1-year return of -42.45%.
Is GoodRx Holdings, Inc. overvalued or undervalued?
As of June 12, 2025, GoodRx Holdings, Inc. is considered undervalued with an attractive valuation grade, a P/E ratio of 38, and strong peer comparisons, despite a recent 1-month return of 25.4% and a year-over-year decline of 39.33%.
Is GoodRx Holdings, Inc. technically bullish or bearish?
As of June 9, 2025, the market trend is mildly bearish, indicated by daily moving averages, while weekly indicators show mixed signals, suggesting a lack of strong momentum.
What does GoodRx Holdings, Inc. do?
GoodRx Holdings, Inc. is a holding company that offers a prescription price comparison tool, categorized as a small-cap company with a market cap of approximately $1.57 billion. As of March 2025, it reported net sales of $203 million and a net profit of $11 million.
How big is GoodRx Holdings, Inc.?
As of Jun 18, GoodRx Holdings, Inc. has a market capitalization of $1,567.97 million, with net sales of $797.41 million and a net profit of $28.44 million for the latest four quarters. The balance sheet as of Dec'24 shows shareholder's funds of $724.66 million and total assets of $1,388.07 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
